Pharma BD Deal Intelligence
Roche's $3.4B acquisition of Ventana Medical Systems—completed after raising its hostile bid from $75 to $89.50/share—brought the leader in automated tissue-based cancer diagnostics in-house. Ventana's IHC/ISH platforms became Roche Tissue Diagnostics, enabling companion diagnostic development.
Hostile takeover created precision medicine diagnostics powerhouse testing 41M patients
Full analysis, sources & comparables →Roche acquired Ventana Medical Systems for $3.4B for tissue diagnostics and pathology solutions.
Roche Holding AG to acquire Ventana Medical Systems Inc for $89.50 per share in definitive merger agreement to boost cancer testing business.
Ventana Medical Systems and Roche Tissue Diagnostics change the pathology landscape over 40 years since the acquisition transformed cancer diagnostics.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Roche acquired Ventana Medical Systems for $89.50 per share in cash (approximately $3.4 billion), after an initial hostile bid of $75 per share was rejected. Ventana was a leader in automated tissue-based diagnostics for cancer and infectious disease, and became Roche Tissue Diagnostics.
Roche Holding AG closes acquisition/merger of Ventana Medical Systems Inc. for $3.4B, establishing strategic position and initiating integration.
Roche acquired Ventana for $3.4B after hostile bid creating Roche Tissue Diagnostics testing 41M patients annually with CDx for key oncology franchises.
Roche acquired Ventana for $3.4B gaining tissue diagnostics leadership enabling CDx for key oncology franchises now testing 41M patients annually.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Ventana Medical Systems Inc. (this deal) | 2008 | $3.4B | 88 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2008 deals · Roche Holding AG deals · Infectious Disease deals